BeOne Medicines AG
BEIGF
$21.95
-$0.56-2.48%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 33.54% | 36.43% | 39.28% | 48.42% | 48.23% |
| Total Other Revenue | 126.45% | 193.49% | 239.85% | 501.48% | -- |
| Total Revenue | 34.35% | 37.44% | 40.23% | 49.53% | 49.54% |
| Cost of Revenue | 3.03% | 5.77% | 12.53% | 25.89% | 44.16% |
| Gross Profit | 39.65% | 43.11% | 45.34% | 54.17% | 50.49% |
| SG&A Expenses | 14.08% | 16.88% | 13.68% | 17.34% | 20.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.65% | 13.01% | 11.82% | 14.17% | 19.09% |
| Operating Income | 1,016.65% | 331.93% | 178.69% | 120.99% | 88.35% |
| Income Before Tax | 1,473.41% | 343.85% | 178.21% | 123.73% | 86.11% |
| Income Tax Expenses | 85.58% | 14.92% | 16.22% | 90.91% | 120.68% |
| Earnings from Continuing Operations | 469.12% | 230.75% | 144.50% | 108.28% | 64.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 469.12% | 230.75% | 144.50% | 108.28% | 64.95% |
| EBIT | 1,016.65% | 331.93% | 178.69% | 120.99% | 88.35% |
| EBITDA | 1,240.15% | 781.04% | 244.28% | 145.09% | 110.34% |
| EPS Basic | 448.98% | 225.31% | 142.65% | 107.40% | 65.31% |
| Normalized Basic EPS | 1,718.29% | 361.96% | 186.24% | 117.30% | 93.45% |
| EPS Diluted | 407.16% | 213.85% | 137.66% | 104.85% | 63.29% |
| Normalized Diluted EPS | 1,532.65% | 350.72% | 182.90% | 116.39% | 92.89% |
| Average Basic Shares Outstanding | 3.76% | 3.88% | 3.58% | 3.05% | 2.19% |
| Average Diluted Shares Outstanding | 5.87% | 7.05% | 7.72% | 6.10% | 4.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -1.66% |